CLAIMS

1. (original) An aqueous formulation comprising (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate (I) and cyclodextrin.

2. (previously presented) The formulation of claim 1, comprising from 0.00005 to 9.0 g/l of the compound (I) and from 0.1 to 550 g/l of cyclodextrin.

3. (previously presented) The formulation of claim 1, comprising from 0.0001 to 0.050 g/l of the compound (I) and from 0.2 to 200 g/l cyclodextrin.

4. (previously presented) The formulation of claim 1, comprising from 0.0005 to 0.025 g/l of the compound (I) and from 1 to 50 g/l cyclodextrin.

5. (previously presented) The formulation of claim 1, which has a pH of from 2 to 6.

6. (previously presented) The formulation of claim 1, comprising at least one physiologically tolerated acid.

7. (previously presented) The formulation of claim 6, which comprises citric acid as physiologically tolerated acid.

8. (previously presented) The formulation of claim 1, comprising from 8 to 10 g/l sodium chloride based on the formulation ready for use.

9. (previously presented) The formulation of claim 1, comprising from 0.05 to 2 g/l ethanol based on the formulation ready for use.

10. (previously presented) An administration kit consisting of a) a container comprising the aqueous formulation of claim 1, b) infusion apparatus, where at least the parts which come into contact with the product consist of polyethylene, polypropylene, polyester, polyamide, acrylonitrile-butadiene-styrene copolymers, polypropylene/styrene-ethylene-butylene-styrene or copolymers thereof.

11. (Previously presented) The formulation of claim 1 comprising about 50 g/l of cyclodextrin.

12. (Previously presented) The formulation of claim 1 comprising about 2 g/l of cyclodextrin.

13. (Previously presented) The formulation of claim 1, wherein said formulation is suitable for parenteral administration.

14. (Previously presented) An aqueous formulation comprising (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-l-sulfonate (I) and from 1 to 50 g/l of cyclodextrin.

15. (Previously presented) The formulation of claim 14, wherein the compound (I) is at a concentration of from 0.0005 to 0.025 g/l.

16. (Previously presented) The formulation of claim 14, further comprising from 8 to 10 g/l sodium chloride based on the formulation ready for use.

17. (Previously presented) The formulation of claim 14, further comprising from 0.05 to 2 g/l ethanol based on the formulation ready for use.

18. (Previously presented) The formulation of claim 14, further comprising ethanol, sodium chloride, and citric acid.